New blood test can diagnose mental illness
Researchers at the University of Campinas - Unicamp and the Federal University of São Paulo (UNIFESP) have developed a blood test capable of diagnosing two types of mental illness: schizophrenia and bipolar disorder. To do so, a blood test was performed on people with some of the types of disease and others who did not.
With MRI, physicians were able to identify changes in the molecules of patients with the disease compared to who did not have schizophrenia or bipolar disorder. "We call these molecules biomarkers, they are present in one investigated group and are absent in the other, or they are present in different concentrations," says Professor Ljubica Tasic of the Institute of Chemistry (IQ) at Unicamp, one of the main conductors of development of the technology.
Because there is currently a deficiency in diagnosis, since in many cases the symptoms of both diseases resemble, and the finding is given through medical research and psychology, the researchers decided to develop this test
With the success of the studies, in addition to diagnostic accuracy, there would be greater assertiveness in treatment, which differs from one disease to another. One of the main points of this test, which relies on biological analysis of a small amount of collected blood, is efficacy, agility and objectivity. "9" Mental disorders such as schizophrenia and bipolar disorder are a major challenge for the system of health, bringing serious financial consequences for both developed and Brazilian countries.The absence of cure and the limitations of the available treatments are reflections of the limited knowledge that has of the brain and of its molecular and cellular mechanisms that regulate its functions " , reports the teacher.
Regarding heart problems, 60 women said they had heart attacks or strokes, of which 39 had HPV and 20% of them had no other risk factor, such as obesity, hypertension or smoking. For researchers, HPV seems a plausible candidate to interfere with the functions of a gene called p53. It helps prevent tumors and, when it does not work right, can lead to neoplasms.
The trastuzumab drug ends to be incorporated more broadly by the Unified Health System - SUS, through the Ministry of Health. This medicine, which costs R $ 10,000 per dose, is used in the treatment of breast cancer subtype HER2 +, the most aggressive and affects one-fifth of women with the disease. Currently, more than 3,000 people use this drug for the SUS, which it provides for patients with early and locally advanced breast cancer.